Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 5:01 AM
Ignite Modification Date:
2025-12-25 @ 5:01 AM
NCT ID:
NCT01666418
Eligibility Criteria:
Inclusion criteria:
* Age ≥ 18 years
* Diagnosis of histologically or cytologically confirmed melanoma stage III or IV.
* Fresh tumor tissue must be provided for all subjects for biomarker analysis before (within 14 days prior to treatment start) and during (on day 10 of the pazopanib monotherapy and the last day of the treatment with pazopanib, day 70) treatment with investigational product (asservation in RNAlater, for kryo asservation, and for cell cultures)
* Assessable metastases (skin or superficial lymph nodes with a minimal diameter 1 cm)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
* Adequate organ system function
Exclusion criteria:
* Prior malignancy.
* Central nervous system (CNS) metastases
* Corrected QT interval (QTc) \> 480 msecs using Bazett's formula.
* History of any one or more of the following cardiovascular conditions within the past 6 months:
* Cardiac angioplasty or stenting;
* Myocardial infarction;
* Unstable angina;
* Coronary artery bypass graft surgery;
* Symptomatic peripheral vascular disease;
* Class III or IV congestive heart failure, as defined by the New York Heart Association (NYHA).
* Poorly controlled hypertension
* History of cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or untreated deep venous thrombosis (DVT) within the past 6 months.
* Presence of uncontrolled infection
* Clinically significant gastrointestinal abnormalities that may increase the risk for gastrointestinal bleeding
* Evidence of active bleeding or bleeding diathesis
* Any ongoing toxicity from prior anti-cancer therapy that is \>Grade 1 and/or that is progressing in severity, except alopecia.
* Prior exposure to the study drug pazopanib
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Study:
NCT01666418
Study Brief:
Protocol Section:
NCT01666418